Tell Big Pharm To Make Ebola Vaccine Affordable!

GlaxoSmithKline has begun trials on a vaccine that would protect against the spread of Eblola, and a vaccine may be available as soon as next year. But will it get to the people who need it most--in west Africa?

Unfortunately, big pharmaceutical companies have a history of pricing life-saving medications beyond the reach of the people who most need them. Most HIV patients in Africa cannot begin to afford the US $10,000 a year it costs for medications that can stop or slow the progression of AIDS. And their governments don't have the funds to provide medical assistance to the poor. That means that most African children born with HIV get no treatment.

The Ebola virus is similarly concentrated in Africa. In Sierra Leone, 1,259 people have died of Ebola infection, and there have been 2,704 fatalities in Liberia. Please join me in asking GlaxoSmithKline to price its future Ebola vaccine so that west Africans can afford it.

To Whom It May Concern at GlaxoSmithKline:


We the undersigned thank you for your quick response to the growing Ebola epidemic. However, we are specifically concerned that any future vaccines should be made available to the people who most need them at a price they can afford. Thousands of people have died of Ebola infection in Liberia and Sierra Leone. These are not affluent countries, and the Ebola patients there will be unable to afford medications priced for relatively affluent Westerners. So, we ask that you implement a country-by-country sliding scale or pay down system to make sure that any effective Ebola vaccine can quickly get to the people who need it most. We thank you for your attention to this issue.  

Sign Petition
Sign Petition
You have JavaScript disabled. Without it, our site might not function properly.

Privacy Policy

By signing, you accept Care2's Terms of Service.
You can unsub at any time here.

Having problems signing this? Let us know.